INCY250117C62500
- 7.59
- -4.81-38.79%
Incyte Newsroom
Cantor Fitzgerald Reiterates Neutral on Incyteto Neutral
Incyte Announces Retirement of Executive VP Barry Flannelly
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $74
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Announces Target Price $74
Incyte (INCY) Receives a Hold From Truist Financial
RBC Capital Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $75
Incyte's Strategic Balancing Act: Promising Drug Prospects Amid Competitive and Intellectual Property Challenges
RBC Lifts Price Target on Incyte to $75 From $74, Keeps Sector Perform Rating
Incyte Corp. Stock Rises Tuesday, Still Underperforms Market
How to find the "alpha" market in U.S. stocks next year? Goldman Sachs provides an investment guide.
Zhihui Finance has learned that Goldman Sachs analysts said in a report that over the next six months, the materials, Software, and services industries in the USA are most likely to outperform the Large Cap. Goldman Sachs strategist David Kostin stated in a report on December 20 that they introduced a model for USA Stocks to select industries expected to exceed the benchmark Index by 5 percentage points or more, "to identify 'high conviction' views with significant Alpha potential." He noted, "Our model incorporates macro, fundamental, and valuation data as independent variables. We run probability models separately for each Industry, only including
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Wells Fargo Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $70
Incyte Price Target Raised to $70 From $68 at Wells Fargo
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)
Incyte Analyst Ratings
UBS Initiates Incyte(INCY.US) With Hold Rating, Announces Target Price $77